Subject: Announcement of the approval of the Company's quadrivalent influenza vaccine from China's National Medical Products Administration
· Issued by Adimmune Corporation
Close
Today's Information
Provided by: ADIMMUNE CORPORATION
SEQ_NO
1
Date of announcement
2022/02/11
Time of announcement
13:52:21
Subject
Subject:Announcement of the approval of the
Company's quadrivalent influenza vaccine from China's
National Medical Products Administration
Date of events
2022/02/11
To which item it meets
paragraph 51
Statement
1.Date of occurrence of the event:2022/02/11
2.Company name:Adimmune Corporation
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:The marketing authorization of the Company's
quadrivalent influenza vaccine is granted by China's National Medical
Products Administration
6.Countermeasures:To release this material information
7.Any other matters that need to be specified:Upon receiving the marketing
authorization from China's National Medical Products Administration, the
Company will initiate the marketing of quadrivalent influenza vaccine
for adults. It will have positive impacts on the Company's sales and
finances.
